Adaptive (ADPT) | Financial Analysis & Statements
Adaptive Biotechnologies Corporation Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
71.7M
Gross Profit
53.5M
74.58%
Operating Income
-12.8M
-17.82%
Net Income
-13.6M
-18.94%
EPS (Diluted)
$-0.09
Balance Sheet Metrics
Total Assets
512.7M
Total Liabilities
287.7M
Shareholders Equity
225.0M
Debt to Equity
1.28
Cash Flow Metrics
Operating Cash Flow
-236.0K
Free Cash Flow
1.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Adaptive Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 277.0M | 179.0M | 170.3M | 185.3M | 154.3M |
| Cost of Goods Sold | 71.4M | 72.1M | 75.6M | 57.9M | 49.3M |
| Gross Profit | 205.6M | 106.9M | 94.7M | 127.4M | 105.0M |
| Gross Margin % | 74.2% | 59.7% | 55.6% | 68.7% | 68.1% |
| Operating Expenses | |||||
| Research & Development | 93.8M | 103.0M | 122.1M | 141.8M | 142.3M |
| Selling, General & Administrative | 167.3M | 157.6M | 172.5M | 184.1M | 170.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 261.0M | 260.5M | 294.6M | 325.9M | 312.3M |
| Operating Income | -57.1M | -155.3M | -201.6M | -200.2M | -209.0M |
| Operating Margin % | -20.6% | -86.8% | -118.4% | -108.0% | -135.4% |
| Non-Operating Items | |||||
| Interest Income | 9.4M | 14.5M | 15.5M | 4.1M | 1.7M |
| Interest Expense | 11.8M | 11.6M | 13.8M | 4.2M | 0 |
| Other Non-Operating Income | - | -7.2M | -25.4M | - | - |
| Pre-tax Income | -59.5M | -159.6M | -225.3M | -200.4M | -207.3M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -59.5M | -159.6M | -225.3M | -200.4M | -207.3M |
| Net Margin % | -21.5% | -89.2% | -132.3% | -108.1% | -134.3% |
| Key Metrics | |||||
| EBITDA | -29.8M | -121.6M | -163.8M | -175.2M | -193.3M |
| EPS (Basic) | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 |
| EPS (Diluted) | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 |
| Basic Shares Outstanding | 151721939 | 147101648 | 144383294 | 142515917 | 140354915 |
| Diluted Shares Outstanding | 151721939 | 147101648 | 144383294 | 142515917 | 140354915 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Adaptive Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 70.5M | 47.9M | 65.1M | 90.0M | 139.1M |
| Short-term Investments | 156.5M | 174.4M | 281.3M | 408.2M | 214.0M |
| Accounts Receivable | 50.4M | 41.7M | 38.0M | 40.1M | 17.4M |
| Inventory | 9.8M | 8.4M | 14.4M | 14.5M | 19.3M |
| Other Current Assets | 13.0M | 11.3M | 11.4M | 9.4M | 13.0M |
| Total Current Assets | 300.2M | 283.8M | 410.2M | 562.1M | 402.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 85.2M | 92.7M | 101.7M | 124.4M | 124.0M |
| Goodwill | 239.7M | 241.4M | 243.1M | 244.8M | 246.5M |
| Intangible Assets | 1.7M | 3.4M | 5.1M | 6.8M | 8.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 3.9M | 5.2M | 6.5M | 4.5M | 3.0M |
| Total Non-Current Assets | 212.6M | 255.6M | 250.9M | 294.5M | 520.6M |
| Total Assets | 512.7M | 539.4M | 661.1M | 856.6M | 923.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 6.5M | 7.3M | 7.7M | 8.1M | 3.3M |
| Short-term Debt | 8.9M | 10.2M | 9.4M | 9.2M | 5.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 4.6M | 865.0K | - | - | - |
| Total Current Liabilities | 89.9M | 98.1M | 88.0M | 109.8M | 113.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 70.2M | 79.1M | 89.4M | 98.8M | 106.7M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 126.6M | 132.4M | 130.7M | 125.4M | - |
| Total Non-Current Liabilities | 197.8M | 238.8M | 264.8M | 282.7M | 205.4M |
| Total Liabilities | 287.7M | 336.9M | 352.9M | 392.5M | 319.2M |
| Equity | |||||
| Common Stock | 15.0K | 14.0K | 14.0K | 14.0K | 14.0K |
| Retained Earnings | -1.4B | -1.3B | -1.1B | -919.1M | -718.9M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 225.0M | 202.5M | 308.3M | 464.1M | 604.1M |
| Key Metrics | |||||
| Total Debt | 79.1M | 89.4M | 98.8M | 108.0M | 111.7M |
| Working Capital | 210.3M | 185.7M | 322.2M | 452.4M | 288.9M |
Balance Sheet Composition
Adaptive Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -59.5M | -159.6M | -225.3M | -200.4M | -207.3M |
| Depreciation & Amortization | 17.8M | 19.3M | 22.2M | 20.9M | 14.0M |
| Stock-Based Compensation | 51.5M | 53.6M | 62.9M | 55.5M | 43.3M |
| Working Capital Changes | -56.7M | -18.2M | -38.8M | -82.2M | -62.0M |
| Operating Cash Flow | -43.0M | -96.9M | -166.6M | -198.0M | -205.2M |
| Investing Activities | |||||
| Capital Expenditures | -3.0M | -3.7M | -10.7M | -16.3M | -61.7M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -181.7M | -244.3M | -429.6M | -278.8M | -316.5M |
| Investment Sales | 222.6M | 325.7M | 569.9M | 298.0M | 559.5M |
| Investing Cash Flow | 38.0M | 77.8M | 129.6M | 2.9M | 181.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | 124.4M | 0 |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 12.5M | - | - | 248.8M | 429.0K |
| Free Cash Flow | -48.9M | -98.9M | -167.0M | -200.3M | -254.5M |
| Net Change in Cash | 7.5M | -19.1M | -37.0M | 53.7M | -23.5M |
Cash Flow Trend
Adaptive Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-35.44
Forward P/E
-52.91
Price to Book
9.99
Price to Sales
7.90
PEG Ratio
0.58
Profitability Ratios
Profit Margin
-21.48%
Operating Margin
-17.82%
Return on Equity
-27.82%
Return on Assets
-6.79%
Financial Health
Current Ratio
3.34
Debt to Equity
93.49
Beta
2.30
Per Share Data
EPS (TTM)
$-0.39
Book Value per Share
$1.42
Revenue per Share
$1.83
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ADPT | 2.1B | -35.44 | 9.99 | -27.82% | -21.48% | 93.49 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






